Biovel Live Sciences launches operations in India

Bangalore, July 5 (UNI) Biovel Life Sciences, an integrated biotechnology enterprise, today announced launch of its operations in India.

The Company which has collaborated with US based Dowpharma for the production of Human Growth hormone (HGH) using Pfenex Expression Technology, was focused on the research, manufacturing and marketing of biogenerics and biopharmaceuticals with initiatives in drug development and bioprocessing.

To mark the entry into bio-pharma manufacturing sector, Biovel has signed a licensing agreement with Dowpharma, to utilise path breaking Pfenex Expression Technology to produce HGH for the first time globally.

Addressing a press conference here, Biovel Life Sciences Director (Technical) Chairman and Managing Director P Sudhakera Naidu said that the company would come out with Typhoid, HiB vaccines next year and this would be produced at the state-of-the-art pilot plant established at Hosakote, in the outskirts of the Bangalore. The plant would also produce recombinant proteins like EGF and Streptokinase. "Biovel is also actively pursuing the development of molecules in segments of Oncology, dermatology and gynecology", he added.

Mr Naidu also announced the completion of the first phase of the facility spread across 10 acres. The first phase of the facility consists of an R and D centre, a pilot plant, two independent production lines with 300 L and 100 L fermentors and two independent filling lines with lyophilizzation.

The pilot plant contains a fully automated 19L Fermentor and has the capacity to produce clinical material and to meet Biovel's initial marketing requirements, he added.

Dowpharma Global Business Director Nick Hyde said that Dowpharma would prepare and transfer to biovel a Research Cell Bank and the bench scale process. This technology was based on specially modified strains of 'Pseudomonas fluorenscens' bacteria.

MORE UNI